• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英夫利昔单抗治疗难治性川崎病伴冠状动脉瘤。

Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.

作者信息

Oishi Taku, Fujieda Mikiya, Shiraishi Taisuke, Ono Miki, Inoue Kazuo, Takahashi Akiyoshi, Ogura Hideo, Wakiguchi Hiroshi

机构信息

Department of Pediatrics, Kochi National Hospital, Kochi, Japan.

出版信息

Circ J. 2008 May;72(5):850-2. doi: 10.1253/circj.72.850.

DOI:10.1253/circj.72.850
PMID:18441471
Abstract

Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.

摘要

肿瘤坏死因子-α(TNF-α)被认为是诱发包括川崎病(KD)冠状动脉瘤(CA)在内的血管炎的因素之一,因为与未患冠状动脉瘤的患者相比,患冠状动脉瘤的川崎病患者血液中TNF-α的浓度更高。因此,一名1个月大患有难治性川崎病并伴有冠状动脉瘤的女童接受了抗TNF-α药物(英夫利昔单抗)治疗,随后冠状动脉瘤病情改善,川崎病在发病20个月后得到控制,且未出现并发症。

相似文献

1
Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.英夫利昔单抗治疗难治性川崎病伴冠状动脉瘤。
Circ J. 2008 May;72(5):850-2. doi: 10.1253/circj.72.850.
2
Infliximab treatment for pediatric refractory Kawasaki disease.英夫利昔单抗治疗儿童难治性川崎病。
Pediatr Cardiol. 2011 Oct;32(7):1023-7. doi: 10.1007/s00246-011-0045-2. Epub 2011 Jul 20.
3
[Refractory Kawasaki disease with coronary aneurysms treated with infliximab].[英夫利昔单抗治疗伴有冠状动脉瘤的难治性川崎病]
An Pediatr (Barc). 2010 Nov;73(5):268-71. doi: 10.1016/j.anpedi.2010.06.006. Epub 2010 Aug 3.
4
Infliximab as a novel therapy for refractory Kawasaki disease.英夫利昔单抗作为难治性川崎病的一种新疗法。
J Rheumatol. 2004 Apr;31(4):808-10.
5
Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.一名幼儿的不完全性和非典型川崎病:对英夫利昔单抗有反应的严重、难治性疾病。
Clin Pediatr (Phila). 2007 May;46(4):345-8. doi: 10.1177/0009922806294842.
6
Kawasaki disease. Involution of giant coronary aneurysms after prolonged anti-inflammatory treatment.川崎病。长期抗炎治疗后巨大冠状动脉瘤的消退。
Arq Bras Cardiol. 2003 Sep;81(3):265-72.
7
Kawasaki disease with giant coronary artery aneurysms.川崎病合并巨大冠状动脉瘤
Coron Artery Dis. 2017 Mar;28(2):177-179. doi: 10.1097/MCA.0000000000000437.
8
Extensive coronary aneurysms with thrombosis in resistant Kawasaki disease.难治性川崎病伴广泛冠状动脉瘤及血栓形成
Pediatr Cardiol. 2013 Feb;34(2):444-6. doi: 10.1007/s00246-012-0285-9. Epub 2012 Mar 18.
9
Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.英夫利昔单抗治疗静脉注射免疫球蛋白治疗抵抗川崎病患儿的疗效和局限性:一项开放标签病例系列报告。
J Rheumatol. 2012 Apr;39(4):864-7. doi: 10.3899/jrheum.110877. Epub 2012 Feb 15.
10
Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.川崎病后冠状动脉瘤形成的相关因素,对于及时接受治疗的患者和延迟治疗或未接受治疗的患者而言是相似的。
Int J Cardiol. 2017 Jun 1;236:157-161. doi: 10.1016/j.ijcard.2017.01.068. Epub 2017 Jan 8.

引用本文的文献

1
Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.静脉注射免疫球蛋白γ(IVIG)与 IVIG 联合英夫利昔单抗治疗川崎病患儿的比较
Med Sci Monit. 2018 Oct 11;24:7264-7270. doi: 10.12659/MSM.908678.
2
Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.川崎病:意大利儿科学会指南,第二部分——抵抗形式和心血管并发症的治疗、随访、生活方式和心血管风险预防。
Ital J Pediatr. 2018 Aug 30;44(1):103. doi: 10.1186/s13052-018-0529-2.
3
Kawasaki Disease.
川崎病
Front Pediatr. 2018 Jul 10;6:198. doi: 10.3389/fped.2018.00198. eCollection 2018.
4
Treatment Options for Resistant Kawasaki Disease.难治性川崎病的治疗选择
Paediatr Drugs. 2018 Feb;20(1):59-80. doi: 10.1007/s40272-017-0269-6.
5
Cordycepin inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via activating amp-activated protein kinase (AMPK) signaling.虫草素通过激活腺苷酸活化蛋白激酶(AMPK)信号通路抑制脂多糖(LPS)诱导的肿瘤坏死因子(TNF)-α生成。
Int J Mol Sci. 2014 Jul 8;15(7):12119-34. doi: 10.3390/ijms150712119.
6
Management of Kawasaki disease.川崎病的治疗。
Arch Dis Child. 2014 Jan;99(1):74-83. doi: 10.1136/archdischild-2012-302841. Epub 2013 Oct 25.
7
Clinical use of biologics in vasculitis syndromes.生物制剂在血管炎综合征中的临床应用。
Biologics. 2012;6:371-8. doi: 10.2147/BTT.S37537. Epub 2012 Oct 25.
8
Recent understanding on diagnosis and management of central nervous system vasculitis in children.儿童中枢神经系统血管炎诊断与管理的最新认识
Clin Dev Immunol. 2012;2012:698327. doi: 10.1155/2012/698327. Epub 2012 Sep 12.
9
Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge.3 月龄婴儿对 IVIG 无反应的川崎病灾难性表现:诊断和治疗挑战。
Pediatr Rheumatol Online J. 2012 Aug 28;10(1):28. doi: 10.1186/1546-0096-10-28.
10
Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.白细胞介素-1β 在川崎病小鼠模型中对冠状动脉炎症的诱导至关重要。
Circulation. 2012 Mar 27;125(12):1542-50. doi: 10.1161/CIRCULATIONAHA.111.072769. Epub 2012 Feb 23.